

Rainer F Storb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6866172/publications.pdf>

Version: 2024-02-01

264
papers

39,756
citations

8181

76
h-index

2571

195
g-index

267
all docs

267
docs citations

267
times ranked

14976
citing authors

#	ARTICLE	IF	CITATIONS
1	Commentary on the 1962<i>Transfusion</i> paper by Don Thomas and Joe Ferrebee. <i>Transfusion</i> , 2022, 62, 16-21.	1.6	0
2	Cancers after HLA-matched related bone marrow transplantation for aplastic anemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 83-88.	2.4	6
3	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. <i>Blood</i> , 2022, 139, 1694-1706.	1.4	36
4	Transcutaneous ultrasound-mediated gene delivery into canine livers achieves therapeutic levels of factor VIII expression. <i>Blood Advances</i> , 2022, 6, 3557-3568.	5.2	2
5	Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2022, 36, 1563-1574.	7.2	2
6	Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high-grade B-cell lymphoma. <i>Veterinary and Comparative Oncology</i> , 2022, 20, 862-870.	1.8	2
7	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <i>Haematologica</i> , 2021, 106, 1599-1607.	3.5	18
8	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 163.e1-163.e7.	1.2	0
9	Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization". <i>Transplantation and Cellular Therapy</i> , 2021, 27, 476.e1-476.e7.	1.2	4
10	Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation. <i>Veterinary Medicine and Science</i> , 2021, 7, 2156-2171.	1.6	2
11	Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD. <i>Transplantation</i> , 2021, 105, 1008-1016.	1.0	2
12	EASIX and mortality after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 553-561.	2.4	70
13	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	2.4	10
14	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	3.9	157
15	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1811-1818.	2.0	4
16	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2020, 12, 2339.	3.7	28
17	Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 471-483.	1.8	2
18	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	7.2	22
20	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1332-1341.	2.0	24
21	History of hematopoietic cell transplantation: challenges and progress. <i>Haematologica</i> , 2020, 105, 2716-2729.	3.5	54
22	CD94 Ex Vivo Cultures in a Bone Marrow Transplantation Setting. <i>Transplantation Direct</i> , 2020, 6, e632.	1.6	0
23	Total Body Irradiation-Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e356-e362.	2.0	11
24	Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2152-2159.	2.0	14
25	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	4.6	84
26	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. <i>Haematologica</i> , 2019, 104, 1221-1229.	3.5	14
27	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1331-1339.	2.0	17
28	Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2019, 133, 2790-2799.	1.4	81
29	Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. <i>Veterinary Immunology and Immunopathology</i> , 2019, 211, 10-18.	1.2	14
30	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019, 54, 1511-1514.	2.4	1
31	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
32	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	3.5	25
33	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
34	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <i>Bone Marrow Transplantation</i> , 2018, 53, 1304-1310.	2.4	12
35	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect. <i>Haematologica</i> , 2018, 103, e252-e255.	3.5	2
36	Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 50-54.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2211-2215.	2.0	9
38	Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation. <i>ILAR Journal</i> , 2018, 59, 263-275.	1.8	6
39	Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. <i>Blood Advances</i> , 2018, 2, 2020-2028.	5.2	81
40	Induction of Tolerance towards Solid Organ Allografts Using Hematopoietic Cell Transplantation in Large Animal Models. <i>OBM Transplantation</i> , 2018, 3, 1-1.	0.2	4
41	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018, 132, 5255-5255.	1.4	0
42	Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1669-1677.	2.0	45
43	A Canine Model of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 420-427.	2.0	14
44	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e414-e423.	4.6	92
45	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , 2017, 1, 2247-2256.	5.2	15
46	Evaluation of allogeneic transplantation in first or later minimal residual disease negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	1.3	28
47	Nonmyeloablative allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 521-530.	3.5	46
48	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508.	1.4	174
49	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
50	RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. <i>Cell Stem Cell</i> , 2016, 19, 599-612.	11.1	97
51	Long-term Tolerance Toward Haploidentical Vascularized Composite Allograft Transplantation in a Canine Model Using Bone Marrow or Mobilized Stem Cells. <i>Transplantation</i> , 2016, 100, e120-e127.	1.0	15
52	Minor Antigen Vaccine-Sensitized DLI. <i>Transplantation Direct</i> , 2016, 2, e71.	1.6	0
53	Addition of Astatine-211-Labeled Anti-CD45 Antibody to Total Body Irradiation (TBI) As Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model. <i>Blood</i> , 2016, 128, 2152-2152.	1.4	1
54	Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2015, 99, 2083-2094.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2015, 170, 574-583.	2.5	45
56	Anti-CD28 Antibody-Initiated Cytokine Storm in Canines. Transplantation Direct, 2015, 1, 1-11.	1.6	13
57	¹¹¹ In-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After ²¹¹ At-Radioimmunotherapy for Hematopoietic Cell Transplantation. Journal of Nuclear Medicine, 2015, 56, 1766-1773.	5.0	18
58	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. Biology of Blood and Marrow Transplantation, 2015, 21, 373-378.	2.0	30
59	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 848-854.	2.0	40
60	Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica, 2015, 100, 842-848.	3.5	75
61	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1418-1424.	2.0	62
62	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
63	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 105-112.	2.0	47
64	Simultaneous Transplantation of Hematopoietic Stem Cells and a Vascularized Composite Allograft Leads to Tolerance. Transplantation, 2014, 98, 131-138.	1.0	32
65	Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial. Biology of Blood and Marrow Transplantation, 2014, 20, 1996-2003.	2.0	51
66	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 3249-3256.	1.6	361
67	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1363-1368.	2.0	54
68	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica, 2014, 99, 1624-1631.	3.5	33
69	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood, 2014, 124, 287-295.	1.4	83
70	Fludarabine and 2-Gy TBI is Superior to 2Â Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1340-1347.	2.0	23
71	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2013, 19, 792-798.	2.0	27
72	Comparing High and Low Total Body Irradiation Dose Rates for Minimum-Intensity Conditioning of Dogs for Dog Leukocyte Antigen-Identical Bone Marrow Grafts. Biology of Blood and Marrow Transplantation, 2013, 19, 1650-1654.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. <i>Leukemia and Lymphoma</i> , 2013, 54, 1591-1601.	1.3	40
74	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	1.6	197
75	Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation. <i>Chimerism</i> , 2013, 4, 95-101.	0.7	8
76	Inducible Costimulator (ICOS) Up-Regulation on Activated T Cells in Chronic Graft-Versus-Host Disease After Dog Leukocyte Antigenâ€“Nonidentical Hematopoietic Cell Transplantation, 2013, 96, 34-41.	1.0	18
77	Long-Term Tolerance to Kidney Allografts After Induced Rejection of Donor Hematopoietic Chimerism in a Preclinical Canine Model. <i>Transplantation</i> , 2012, 94, 562-568.	1.0	17
78	Durable donor engraftment after radioimmunotherapy using ^{131}I -emitter astatine-211â€“labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 1130-1138.	1.4	52
79	Mesenchymal Stromal Cells: A New Tool against Graft-versus-Host Disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 822-840.	2.0	99
80	Success of allogeneic marrow transplantation for children with severe aplastic anaemia. <i>British Journal of Haematology</i> , 2012, 158, 120-128.	2.5	23
81	Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complexâ€“haplo-identical non-myeloablative hematopoietic cell transplantation. <i>Cytotherapy</i> , 2011, 13, 1269-1280.	0.7	17
82	Canine Bone Marrow-Derived Mesenchymal Stromal Cells Suppress Alloreactive Lymphocyte Proliferation in Vitro but Fail to Enhance Engraftment in Canine Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 465-475.	2.0	55
83	Mesenchymal Stromal Cells Fail to Prevent Acute Graft-versus-Host Disease and Graft Rejection after Dog Leukocyte Antigen-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 214-225.	2.0	45
84	Pharmacological Immunosuppression Reduces But Does Not Eliminate the Need for Total-Body Irradiation in Nonmyeloablative Conditioning Regimens for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1255-1260.	2.0	5
85	A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1088-1092.	2.0	35
86	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	1.4	544
87	Antagonistic and Agonistic Anti-canine CD28 Monoclonal Antibodies: Tools for Allogeneic Transplantation. <i>Transplantation</i> , 2011, 91, 833-840.	1.0	22
88	Tolerance to Vascularized Composite Allografts in Canine Mixed Hematopoietic Chimeras. <i>Transplantation</i> , 2011, 92, 1301-1308.	1.0	51
89	90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. <i>Blood</i> , 2011, 118, 1132-1139.	1.4	62
90	Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. <i>Blood</i> , 2011, 118, 1421-1428.	1.4	75

#	ARTICLE	IF	CITATIONS
91	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	1.4	113
92	Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. <i>Haematologica</i> , 2011, 96, 1838-1845.	3.5	47
93	Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2011, 96, 1113-1120.	3.5	95
94	Evaluation of Posttransplant Methotrexate to Facilitate Engraftment in the Canine Major Histocompatibility Complex-Haploidentical Nonmyeloablative Transplant Model. <i>Transplantation</i> , 2010, 90, 14-22.	1.0	1
95	The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 149, 101-110.	2.5	46
96	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	1.6	321
97	A Preclinical Canine Model for Composite Tissue Transplantation. <i>Journal of Reconstructive Microsurgery</i> , 2010, 26, 201-207.	1.8	19
98	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39
99	Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-Identical Siblings for Severe Aplastic Anemia in Patients Over 40 Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1411-1418.	2.0	41
100	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	27.0	1,335
101	Allogeneic hematopoietic cell transplantation: the state of the art. <i>Expert Review of Hematology</i> , 2010, 3, 285-299.	2.2	142
102	Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the β^{\pm} -Emitting Radionuclides Bismuth-213 or Astatine-211. <i>Cancer Research</i> , 2009, 69, 2408-2415.	0.9	47
103	Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 4759-4768.	7.0	41
104	Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. <i>Experimental Hematology</i> , 2009, 37, 143-150.	0.4	8
105	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 580-588.	2.0	52
106	Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 694-703.	2.0	70
107	Delaying DLA-Haploidentical Hematopoietic Cell Transplantation after Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1244-1250.	2.0	11
108	Establishment of Long-Term Tolerance to SRBC in Dogs by Recombinant Canine CTLA4-Ig. <i>Transplantation</i> , 2009, 88, 317-322.	1.0	23

#	ARTICLE	IF	CITATIONS
109	Allogeneic hematopoietic cell transplantation after conditioning with 131Iâ€“anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 5444-5453.	1.4	161
110	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. <i>Blood</i> , 2009, 113, 2888-2894.	1.4	115
111	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009, 113, 3383-3391.	1.4	106
112	Development and in vitro characterization of canine CD40-Ig. <i>Veterinary Immunology and Immunopathology</i> , 2008, 123, 260-265.	1.2	8
113	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
114	Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 161-179.	3.1	17
115	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 4912-4920.	1.6	257
116	Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs. <i>Molecular Therapy</i> , 2008, 16, 1340-1346.	8.2	29
117	Intensified Postgrafting Immunosuppression Failed to Assure Long-Term Engraftment of Dog Leukocyte Antigen-Identical Canine Marrow Grafts After 1 Gray Total Body Irradiation. <i>Transplantation</i> , 2008, 85, 1023-1029.	1.0	21
118	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	27.0	479
119	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2007, 110, 2744-2748.	1.4	156
120	Hematopoietic cell transplantationâ€“specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	1.4	292
121	Long-Term Tolerance to Kidney Allografts in a Preclinical Canine Model. <i>Transplantation</i> , 2007, 84, 545-547.	1.0	22
122	CD154 Blockade and Donor-Specific Transfusions in DLA-Identical Marrow Transplantation in Dogs Conditioned with 1-Gy Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 164-171.	2.0	32
123	Hematopoietic Cell Transplantation Directly into Dystrophic Muscle Fails to Reconstitute Satellite Cells and Myofibers. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 886-888.	2.0	12
124	Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning. <i>Blood</i> , 2007, 110, 418-423.	1.4	26
125	Comorbidity and Disease Statusâ€“Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4246-4254.	1.6	380
126	Can reduced-intensity allogeneic transplantation cure older adults with AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 85-90.	1.7	35

#	ARTICLE	IF	CITATIONS
127	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2006, 24, 444-453.	1.6	243
128	Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 899-904.	2.0	12
129	Dog Leukocyte Antigen-Haploidentical Stem Cell Allografts After Anti-CD44 Therapy and Nonmyeloablative Conditioning in a Preclinical Canine Model. <i>Transplantation</i> , 2006, 82, 332-339.	1.0	13
130	Partial Donor-Specific Tolerance to Delayed Skin Grafts After Rejection of Hematopoietic Cell Graft. <i>Transplantation</i> , 2006, 82, 629-637.	1.0	12
131	Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. <i>Journal of the American Veterinary Medical Association</i> , 2006, 228, 728-732.	0.5	26
132	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. <i>Molecular Therapy</i> , 2006, 13, 26-41.	8.2	64
133	Platelet and Red Blood Cell (RBC) Transfusion Requirements of Nonmyeloablative (NM) HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation (HCT): Influence of Genetic Disparity and ABO-Incompatibility.. <i>Blood</i> , 2006, 108, 2985-2985.	1.4	1
134	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. <i>Blood</i> , 2006, 108, 755-755.	1.4	0
135	Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.. <i>Blood</i> , 2006, 108, 413-413.	1.4	0
136	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. <i>Blood</i> , 2005, 106, 2912-2919.	1.4	2,427
137	Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. <i>Blood</i> , 2005, 106, 4002-4008.	1.4	78
138	Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. <i>British Journal of Haematology</i> , 2005, 130, 747-751.	2.5	99
139	Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. <i>American Journal of Kidney Diseases</i> , 2005, 45, 502-509.	1.9	99
140	Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 1-13.	2.5	29
141	Postgrafting Immune Suppression Combined with Nonmyeloablative Conditioning for Transplantation of HLA-Identical Hematopoietic Cell Grafts: Results of a Phase I Study for Treatment of Immunodeficiency Disorders.. <i>Blood</i> , 2005, 106, 327-327.	1.4	1
142	Stable Mixed Hematopoietic Chimerism in Dogs Conditioned with Donor Antigen, Anti-CD154 Antibody and 100cGy TBI.. <i>Blood</i> , 2005, 106, 5210-5210.	1.4	0
143	DLA-Haploidentical Stem Cell Allografts after Anti-CD44 Therapy and Nonmyeloablative Conditioning: The Impact of Donor Lymphocyte Infusion (DLI), Pentostatin and Graft Composition on Donor Chimerism and Rejection.. <i>Blood</i> , 2005, 106, 2194-2194.	1.4	0
144	Molecular cloning and characterization of canine ICOS. <i>Genomics</i> , 2004, 84, 730-736.	2.9	4

#	ARTICLE	IF	CITATIONS
145	Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. <i>Blood</i> , 2004, 103, 78-84.	1.4	151
146	Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. <i>Blood</i> , 2004, 104, 961-968.	1.4	300
147	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2004, 104, 2254-2262.	1.4	226
148	Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. <i>Blood</i> , 2004, 104, 4311-4318.	1.4	75
149	Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.. <i>Blood</i> , 2004, 104, 1202-1202.	1.4	0
150	Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. <i>Experimental Hematology</i> , 2003, 31, 168-175.	0.4	22
151	Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 674-682.	2.0	8
152	Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 489-495.	2.0	40
153	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 756-762.	1.4	531
154	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i> , 2003, 101, 1620-1629.	1.4	424
155	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454.	1.4	382
156	Selective T-cell ablation with bismuth-213â€“labeled anti-TCRÎ±Î² as nonmyeloablative conditioning for allogeneic canine marrow transplantation. <i>Blood</i> , 2003, 101, 5068-5075.	1.4	65
157	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. <i>Blood</i> , 2003, 102, 2021-2030.	1.4	320
158	Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 2777-2785.	1.4	249
159	Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras1. <i>Transplantation</i> , 2002, 73, 1487-1493.	1.0	49
160	Bismuth 213â€“labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. <i>Blood</i> , 2002, 100, 318-326.	1.4	86
161	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 415-419.	1.4	403
162	Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 512-520.	2.0	236

#	ARTICLE	IF	CITATIONS
163	Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 14-24.	2.0	42
164	Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 513-516.	2.0	17
165	G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 613-619.	2.0	42
166	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	1.4	1,306
167	Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers. <i>New England Journal of Medicine</i> , 2001, 344, 175-181.	27.0	905
168	Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2134-2141.	1.6	79
169	Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. <i>Blood</i> , 2001, 98, 3505-3512.	1.4	119
170	Allogeneic Marrow Engraftment Following Whole Body Irradiation in a Patient with Leukemia. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 201-208.	1.8	25
171	Nonmyeloablative Hematopoietic Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 328-339.	3.8	65
172	Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. <i>Blood</i> , 2000, 96, 3991-3994.	1.4	59
173	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996.	1.4	122
174	CYTOTOXIC T LYMPHOCYTE ANTIGEN 4-IMMUNOGLOBULIN FUSION PROTEIN COMBINED WITH METHOTREXATE/CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PREVENTION IN A CANINE DOG LEUKOCYTE ANTIGEN-NONIDENTICAL MARROW TRANSPLANT MODEL1. <i>Transplantation</i> , 2000, 69, 450-454.	1.0	23
175	Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigen-Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplantation. <i>Blood</i> , 1999, 94, 1131-1136.	1.4	143
176	Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 1999, 94, 1237-1247.	1.4	284
177	Stable Mixed Hematopoietic Chimerism in Dogs Given Donor Antigen, CTLA4Ig, and 100 cGy Total Body Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplant. <i>Blood</i> , 1999, 94, 2523-2529.	1.4	137
178	Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting. <i>Annals of the New York Academy of Sciences</i> , 1999, 872, 372-376.	3.8	50
179	Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 1999, 105, 361-365.	2.5	18
180	Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 155-161.	2.0	15

#	ARTICLE	IF	CITATIONS
181	Synergism Between Mycophenolate Mofetil and Cyclosporine in Preventing Graft-Versus-Host Disease Among Lethally Irradiated Dogs Given DLA-Nonidentical Unrelated Marrow Grafts. Blood, 1998, 91, 2581-2587.	1.4	134
182	Characterization of Monoclonal Antibodies That Recognize Canine CD34. Blood, 1998, 91, 1977-1986.	1.4	85
183	Evidence for Circulating Bone Marrow-Derived Endothelial Cells. Blood, 1998, 92, 362-367.	1.4	1,582
184	CANINE T CELLS TRANSDUCE WITH A HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE. Transplantation, 1998, 66, 540-544.	1.0	13
185	Epitope Specificity of CD44 for Monoclonal Antibody-Dependent Facilitation of Marrow Engraftment in a Canine Model. Blood, 1998, 91, 3494-3502.	1.4	20
186	Solid Cancers after Bone Marrow Transplantation. New England Journal of Medicine, 1997, 336, 897-904.	27.0	914
187	Quasielastic light scattering study of the living human lens as a function of age. Current Eye Research, 1997, 16, 197-207.	1.5	43
188	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. Blood, 1997, 89, 4226-4235.	1.4	358
189	Stable Mixed Hematopoietic Chimerism in DLA-Identical Littermate Dogs Given Sublethal Total Body Irradiation Before and Pharmacological Immunosuppression After Marrow Transplantation. Blood, 1997, 89, 3048-3054.	1.4	584
190	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. Blood, 1997, 90, 4705-4709.	1.4	303
191	Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. British Journal of Haematology, 1997, 98, 1010-1016.	2.5	66
192	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. Blood, 1997, 90, 4705-4709.	1.4	7
193	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. British Journal of Haematology, 1996, 92, 699-706.	2.5	48
194	Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor. Stem Cells, 1996, 14, 90-105.	3.2	77
195	HISTOCOMPATIBILITY TESTING OF DOG FAMILIES WITH HIGHLY POLYMORPHIC MICROSATELLITE MARKERS ¹ . Transplantation, 1996, 62, 876-877.	1.0	118
196	Allogeneic marrow grafts from donors with congenital chromosomal abnormalities in marrow cells. British Journal of Haematology, 1995, 90, 595-601.	2.5	7
197	An Update on Allogeneic Marrow Transplantation for Myelodysplastic Syndrome. Leukemia and Lymphoma, 1995, 17, 95-99.	1.3	41
198	USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING. Transplantation, 1994, 58, 701-706.	1.0	76

#	ARTICLE	IF	CITATIONS
199	Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). British Journal of Haematology, 1993, 84, 515-520.	2.5	36
200	Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. British Journal of Haematology, 1993, 85, 182-184.	2.5	9
201	Implanted Right Atrial Catheters for Continuous Infusion of Solutions into Dogs. Journal of Investigative Surgery, 1993, 6, 461-467.	1.3	6
202	FK-506 AND METHOTREXATE PREVENT GRAFT-VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN-NONIDENTICAL DONORS. Transplantation, 1993, 56, 800-807.	1.0	53
203	A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. British Journal of Haematology, 1992, 80, 49-54.	2.5	35
204	PREVENTION OF TRANSFUSION-INDUCED SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DLA-IDENTICAL CANINE MARROW GRAFTS BY GAMMA IRRADIATION OF MARROW DONOR BLOOD. Transplantation, 1991, 52, 956-959.	1.0	30
205	Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Human Immunology, 1990, 29, 79-91.	2.4	325
206	Bone marrow transplantation in canine GM1 gangliosidosis. Clinical Genetics, 1990, 38, 274-280.	2.0	22
207	Batten's disease: failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model. Clinical Genetics, 1990, 37, 264-270.	2.0	34
208	Secondary Cancers after Bone Marrow Transplantation for Leukemia or Aplastic Anemia. New England Journal of Medicine, 1989, 321, 784-789.	27.0	401
209	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. British Journal of Haematology, 1989, 72, 567-572.	2.5	95
210	Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia. British Journal of Haematology, 1988, 69, 23-28.	2.5	69
211	FACILITATION OF ENGRAFTMENT OF DLA-NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION. Transplantation, 1987, 44, 607-613.	1.0	26
212	ENGRAFTMENT OF DLA-NONIDENTICAL BONE MARROW FACILITATED BY RECIPIENT TREATMENT WITH ANTI-CLASS II MONOCLONAL ANTIBODY AND METHOTREXATE. Transplantation, 1987, 44, 340-345.	1.0	8
213	In vitro immunoglobulin production, proliferation, and cell markers before and after antithymocyte globulin therapy in patients with aplastic anemia. American Journal of Hematology, 1987, 26, 1-15.	4.1	7
214	Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. British Journal of Haematology, 1987, 66, 115-121.	2.5	76
215	Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. British Journal of Haematology, 1987, 66, 115-121.	2.5	2
216	CURE OF MALIGNANT LYMPHOMA IN DOGS WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. Transplantation, 1986, 42, 19-22.	1.0	38

#	ARTICLE	IF	CITATIONS
217	The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. <i>Journal of Clinical Immunology</i> , 1986, 6, 389-396.	3.8	45
218	Canine platelet alloimmunization: the role of donor selection. <i>British Journal of Haematology</i> , 1986, 63, 713-727.	2.5	41
219	Early and late interstitial pneumonia following human bone marrow transplantation. <i>International Journal of Cell Cloning</i> , 1986, 4, 107-121.	1.6	52
220	Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia. <i>New England Journal of Medicine</i> , 1986, 314, 729-735.	27.0	1,353
221	TREATMENT OF HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE WITH ANTITHYMOCYTE GLOBULIN AND CYCLOSPORINE WITH OR WITHOUT METHYLPREDNISOLONE. <i>Transplantation</i> , 1985, 40, 162-166.	1.0	70
222	MARROW TRANSPLANT STUDIES IN DOGS WITH MALIGNANT LYMPHOMA. <i>Transplantation</i> , 1985, 39, 499-503.	1.0	28
223	Graft-versus-Host Disease in Dog and Man: The Seattle Experience. <i>Immunological Reviews</i> , 1985, 88, 215-238.	6.0	152
224	Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft-versus-host disease. <i>Medical and Pediatric Oncology</i> , 1985, 13, 165-172.	1.0	69
225	Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings. <i>New England Journal of Medicine</i> , 1985, 313, 765-771.	27.0	786
226	Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. <i>American Journal of Medicine</i> , 1985, 78, 978-983.	1.5	73
227	Is the Leucocyte groupâ€ša antigen associated with reduced NK cell function?. <i>Tissue Antigens</i> , 1985, 25, 107-110.	1.0	5
228	Allogeneic Marrow Transplantation. <i>Cancer Investigation</i> , 1984, 2, 27-38.	1.3	29
229	BONE MARROW TRANSPLANTATION: A REVIEW OF DELAYED COMPLICATIONS. <i>British Journal of Haematology</i> , 1984, 57, 185-208.	2.5	160
230	Marrow transplantation in hepatitis-associated aplastic anemia. <i>American Journal of Hematology</i> , 1984, 17, 269-278.	4.1	35
231	Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapy. <i>Hematological Oncology</i> , 1984, 2, 151-168.	1.7	70
232	COMBINED IMMUNOSUPPRESSION WITH CYCLOSPORINE AND METHOTREXATE IN DOGS GIVEN BONE MARROW GRAFTS FROM DLA-HAPLOIDENTICAL LITTERMATES. <i>Transplantation</i> , 1984, 37, 62-64.	1.0	47
233	Allogeneic Bone-Marrow Transplantation. <i>Immunological Reviews</i> , 1983, 71, 77-102.	6.0	306
234	Graft-versus-Host Disease and Survival in Patients with Aplastic Anemia Treated by Marrow Grafts from HLA-Identical Siblings. <i>New England Journal of Medicine</i> , 1983, 308, 302-307.	27.0	444

#	ARTICLE	IF	CITATIONS
235	Predictive Factors in Chronic Graft-Versus-Host Disease in Patients with Aplastic Anemia Treated by Marrow Transplantation from HLA-Identical Siblings. <i>Annals of Internal Medicine</i> , 1983, 98, 461.	3.9	264
236	The canine major histocompatibility complex. <i>Tissue Antigens</i> , 1983, 21, 360-373.	1.0	41
237	CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1982, 34, 30-35.	1.0	107
238	MARROW TRANSPLANTATION FOR THALASSAEMIA. <i>Lancet</i> , The, 1982, 320, 227-229.	13.7	300
239	Specific suppressor cells in graft-versus-host tolerance of HLA-identical marrow transplantation. <i>Nature</i> , 1981, 292, 355-357.	27.8	60
240	Antileukemic Effect of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 1981, 304, 1529-1533.	27.0	1,049
241	Detection of the Leukocyte Group-5 Antigens on Normal and Leukemic Lymphocytes with the Antibody-Dependent Cell-Mediated Cytotoxicity Assay. <i>Tissue Antigens</i> , 1981, 17, 174-178.	1.0	3
242	Marrow Transplantation in Thirty "Untransfused" Patients with Severe Aplastic Anemia. <i>Annals of Internal Medicine</i> , 1980, 92, 30-36.	3.9	230
243	Transplantation of Marrow from an Unrelated Donor to a Patient with Acute Leukemia. <i>New England Journal of Medicine</i> , 1980, 303, 565-567.	27.0	251
244	Chronic graft-versus-host syndrome in man. <i>American Journal of Medicine</i> , 1980, 69, 204-217.	1.5	2,369
245	Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts. <i>New England Journal of Medicine</i> , 1979, 300, 1068-1073.	27.0	1,431
246	Relapse Following Marrow Transplantation for Acute Leukemia. <i>American Journal of Hematology</i> , 1978, 5, 191-202.	4.1	20
247	Marrow Transplantation for Treatment of Aplastic Anemia. <i>New England Journal of Medicine</i> , 1977, 296, 61-66.	27.0	312
248	HEMOPOIETIC GRAFTS BETWEEN DLA-IDENTICAL CANINE LITTERMATES FOLLOWING DIMETHYL MYLERAN. <i>Transplantation</i> , 1977, 24, 349-357.	1.0	61
249	EVIDENCE FOR AN ADDITIONAL LOCUS INVOLVED IN GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1977, 24, 165-174.	1.0	17
250	Dimethyl myleran and autologous marrow grafting for the treatment of spontaneous canine lymphoma. <i>European Journal of Cancer</i> , 1977, 13, 1411-1415.	0.9	14
251	Bone Marrow Transplantation in Patients with Gold-Induced Marrow Aplasia. <i>Arthritis and Rheumatism</i> , 1977, 20, 1043-1048.	6.7	109
252	Severe Hereditary Haemolytic Anaemia in Dogs Treated by Marrow Transplantation. <i>British Journal of Haematology</i> , 1976, 33, 357-362.	2.5	35

#	ARTICLE	IF	CITATIONS
253	Bone Marrow Transplantation for Aplastic Anaemia. British Journal of Haematology, 1975, 31, 83-88.	2.5	1
254	Bone-Marrow Transplantation. New England Journal of Medicine, 1975, 292, 832-843.	27.0	1,635
255	Bone-Marrow Transplantation. New England Journal of Medicine, 1975, 292, 895-902.	27.0	1,360
256	Immune Reactivity in Dogs With Spontaneous Malignancy 2 3. Journal of the National Cancer Institute, 1974, 53, 1049-1056.	6.3	25
257	Paroxysmal Nocturnal Haemoglobinuria and Refractory Marrow Failure Treated by Marrow Transplantation. British Journal of Haematology, 1973, 24, 743-750.	2.5	37
258	APLASTIC ANAEMIA TREATED BY MARROW TRANSPLANTATION. Lancet, The, 1972, 299, 284-289.	13.7	221
259	Canine Hemophilia and Hemopoietic Grafting. Blood, 1972, 40, 234-238.	1.4	26
260	THE EFFECT OF AMETHOPTERIN ON THE IMMUNE RESPONSE. Annals of the New York Academy of Sciences, 1971, 186, 467-474.	3.8	21
261	Studies of Marrow Transplantation, Chemotherapy and Cross-circulation in Canine Lymphosarcoma. Blood, 1971, 37, 349-359.	1.4	27
262	Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. Journal of Clinical Investigation, 1971, 50, 1272-1275.	8.2	67
263	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies. , 0, , 1043-1058.		5
264	Hematopoietic Cell Transplantation for Aplastic Anemia. , 0, , 705-726.		0